

**P&T Motion History
Overactive Bladder**

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
darifenacin fesoterodine fumarate flavoxate HCL mirabegron oxybutynin chloride solifenacin tolterodine tartrate trospium chloride	<p>After considering the evidence of safety, efficacy and special populations for the treatment of over active bladder, I move that darifenacin, fesoterodine fumarate, flavoxate, mirabegron, oxybutynin-gel/patch/tab/solution, solifenacin, tolterodine and trospium are safe and efficacious. These drugs can be subject to therapeutic interchange in the Washington preferred drug list, immediate release formulations cannot be interchanged for a once daily formulations and vice versa. A once daily formulation must be included as a preferred drug on the Washington preferred drug list.</p> <p>Motion: Wiser 2nd: Rowe</p>	October 18, 2017	Yes Johnson Sanderson	Yes Johnson Flatebo	Passed Unanimous